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“PALMOPLANTAR PSORIASIS –  
A COMPARATIVE THERAPEUTIC STUDY” 
 
ABSTRACT 
 
INTRODUCTION 
         Psoriasis is an immunologically mediated inflammatory dermatosis 
characterized by erythematous scaly plaques, extremely variable in clinical 
manifestations ranging from innocuous lesions to life threatening pustular & 
erythrodermic psoriasis. Palmoplantar psoriasis present as hyperkeratotic plaques 
with fissures leading to significant disability. Palmoplantar psoriasis can managed 
with either topical agents, phototherapy or systemic agents 
 
AIMS AND OBJECTIVES 
1) To study the therapeutic efficacy of  a)oral methotrexate, b)hand & foot 
phototherapy using NBUVB,  c)topical calcitriol with clobetasol propionate 
ointment . 
2) To do clinical evaluation using PASI scoring and assess quality of 
improvement using DLQI. 
 
 
MATERIALS AND METHODS  
Sixty patients with palmoplantar psoriasis were randomly selected. Clinical 
examination and necessary investigations were done and PASI scoring calculated 
to assess the area involved. Patients were grouped under three groups.  
 
Group A patients were put on calcipotriol with clobetasol propionate ointment. 
Group B patients had hand and foot NB-UVB. Group C patients were put on tablet 
methotrexate. 
 
OBSERVATION AND RESULTS 
 Thirty three patients were males with male to female ratio of 1.22:1.Mean 
age of patients was 36. Mean duration of illness was 11months. Most of the 
patients were manual labourers. 36 patients had lesions over palms and soles, 9 
palms alone and 15 involving soles. Mean PASI reduction at 16weeks was 
maximum with methotrexate. Compliance was good with methotrexate and topical 
group. Relapse cases were seen with methotrexate. 
 
CONCLUSION 
 There is no significant change in clinico-epidemiology and presentation of 
palmoplantar psoriasis. Methotrexate is the most efficacious modality in treatment 
of palmoplantar psoriasis. 
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INTRODUCTION 
 
 Psoriasis is a common, immunologically mediated inflammatory 
dermatosis with genetic predisposition, characterized by erythematous scaly 
plaques involving the scalp and extensors of limbs affecting 0.5 to 1.5% 
individual’s worldwide. 
 
 Palmoplantar psoriasis (PPP) is a localized form of psoriasis and can 
manifest in many different morphologic patterns, from predominantly 
pustular lesions to thickened, hyperkeratotic plaques and anything in 
between.  
 
 Palmoplantar psoriasis is characterized by erythema, hyperkeratosis 
with surrounding lichenification and coarse scale, resulting in peeling, 
blistering, crusting, fissuring and bleeding. These symptoms may 
significantly interfere with activities, inhibiting patients from closing their 
hands or walking comfortably on their feet, leading to major disability and 
reduction in quality of life.  
 
 Palmoplantar lesions are frequently associated with psoriatic plaques 
elsewhere, but can occur in isolation also. In the absence of generalized 
psoriasis, Palmoplantar psoriasis may present similarly to eczematous forms 
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of dermatitis, such as irritant or allergic contact dermatitis, dyshidrotic 
eczema, atopic eczema, mycosis fungoides, fungal infections, and 
palmoplantarkeratoderma, making the diagnosis difficult. This study aims to 
explore the available data on treatment of palmoplantar psoriasis and its 
unique challenges. 
  
  
 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
 Behcet described psoriasis as an antidote to dermatologists’ ego. It 
still remains the most baffling of dermatoses, proving to be the most 
vulnerable point in their armor as experts. Dermatologists of today can look 
with suspicion at masters of yesterday as apart from diagnosis and palliative 
treatment, nothing much really has been accomplished in the management 
of disease 1. Maybe this is the reason why physician by the name Wilson 
rightly quoted “Psoriasis is not a disease on which to build a medical 
reputation” 
 
 Psoriasis is as old as mankind. Despite its frequency, visibility and 
chronicity, there is very little literature that we can draw from the works of 
ancient physicians. In the 18th century, after the descent of 
protodermatologists, there evolved a new generation of dermatologists who 
started describing the disease more often than not, after which Psoriasis 
became a distinct entity 2. 
 
 Hippocrates (460-377 BC), father of western medicine, in the golden 
age of greek science, described some itchy lesions over eyelids and genitals 
for which he used coal tar and climate as treatment. But this condition was 
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undoubtedly not psoriasis. Stickler et al grouped various skin conditions 
under the term of ‘lopoi’, meaning scale and coined the word ‘alphos’ and 
‘leukos’ for some skin diseases with maculae but doubtless not for 
psoriasis2. 
 
 Celsus in first century AD, in the book “De re medicalibriocto” 
described lesions which appeared on skin of extremities and nails. He 
suggested Pitch and Sulphur as treatment. During these times and later, 
Psoriasis was often confused with Syphilis, Leprosy and other skin 
diseases2. 
 
 Roman encyclopedist Pliny, in his book, “NaturalisHistoria” 
mentions the word psora for which he suggested Cucumber as treatment. 
Galen (131-201 AD) used the word “Psoriasis” for itchy, scaly eruptions 
around eyelids and scrotum which was probably seborrheic dermatitis2. 
 
HeironymusMercurialis (1530-1606 AD) in his work “ 
Demorbiscutaneis et omnibus corporishumaniexcrementis ” described 
psoriasis under the name of   “ Lepragrecorum ” , the other being “ Psora 
Leprosa”2. 
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English physician Robert Wilan(1757-1812) termed Psoriasis for the 
papulosquamous disease under the order “squamae” together with leprosy, 
pityriasis and icthyosis. He described different forms of psoriasis namely 
guttata, diffusa, gyrata, palmaria, unguium and inveterata3. 
 
Ferdinand Von Hebra (1806-1880) from Austria, clearly divided 
psoriasis from leprosy and believed in Arsenic for its treatment2.Besnier and 
later Charles Bourdillon described psoriatic arthritis2. 
 
Despite continuing disputes, dermatology and more so Psoriasis in 
particular, saw tremendous growth and improved upon introduction of new 
histopathological classifications3. 
 
Leo Von Zumbusch (1884-1940) first described GeneralisedPustular 
Psoriasis in 19104. Later in the year 1936, Barber Königsbeck described 
Psoriasis Palmoplantaris and differentiated it from pustulosis of palms and 
soles5. 
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Other important landmarks related to psoriasis were 
1872 – Heinrich Köbner – Kobner’s Phenomenon6 
1885 – Heinrich Auspitz – Auspitz’s sign7 
1878 – Balmanno Squire – Chrysaeobin8 
1898 – William.J.Munro – Munro’s microabscesses9 
1916 – Pau Gerson Unna – Use of Anthralin in treatment10 
1925 –Goeckermann – Combination of Coal Tar with UV-B11 
1926 –Wornoff – Wornoff ring12 
1927 – FranjoKogoj – Spongiform pustules of Kogoj13. 
1953 – John Ingram – Dithranol regimen14 
1970 – Leavall – Treatment with Hydroxyurea15 
1974 – Parrish – Use of 8-methoxypsoralen with UV-A16 
1976 – Fischer – UV-B17 
1986 – Morimoto – Use of Calcipotriol (Vitamin D analogue) 18 
2003 – Alefacept – treatment of psoriasis18 
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PSORIASIS – CURRENT SCENARIO 
 Psoriasis is seen globally. Prevalence ranges somewhere between 
0.1% - 3% in various studies conducted all over the world18. With the life 
expectancy being comparable to normal population and the disease being 
persistent and chronic, the incidence of psoriasis increases with age19.  
 
The incidence ranges from 0.3% in China, 1.4% in United States, 
2.3% in Sweden and 2.8% in France19. 
 
In India, incidence lies between 1% - 6% as reported from various 
dermatology clinics20-24. 
 
Mean age of incidence in males were 36.9±15.10 and in females it 
was found to be 29.34±15.10 24. There must arise suspicion  about family 
history if the onset is earlier25.  
 
Indian studies showed higher prevalence in males(2.5%) than  
females(0.8%) 21,22. 
 
Clinical presentation of psoriasis can be classified into two types, 
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• Type 1 : hereditary form, more common, more severe, strongly 
associated with HLA-Cw6 with increased incidence in 1st and 2nd 
decade26. 
 
• Type 2: sporadic form, less common and less severe, no HLA       
association affecting those in 3rd and 4th decade26. 
 
ETIOLOGY AND PRECIPITATING FACTORS:27 
 Psoriasis is a complex disease that its exact etiology is poorly 
understood. However there are numerous factors which can precipitate 
psoriasis namely, 
 
1. Trauma 
Trauma may be of any form; 
a) Physical 
b) Chemical  
c) Mechanical : heavy labourers 
 
2. Infections 27 
Beta hemolytic streptococcal infections – Upper respiratory tract 
infections, tonsillitis. 
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HIV infection is proven to exacerbate psoriasis27 
 
3. Season28 
Winter exacerbates psoriasis whereas summer is known to bring about 
remission 
 
4. Metabolic factors29 
Hypocalcemia precipitates psoriasis, particularly pustular psoriasis. 
 
5. Endocrine factors30 
Psoriasis reaches its peak during puberty and menopause. Similarly 
studies have shown that psoriasis remits during pregnancy and 
exacerbates during post-partum period. 
 
6. Stress31 
Stress is directly related to psoriasis and psoriasis in turn, will lead to 
depression which in turn will flare up psoriasis. 
 
7. Alcohol32 
Alcoholics with psoriasis will consume excessive amounts of alcohol 
which will increase severity of the disease. 
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8. Drugs33 
Drugs precipitating psoriasis are  
a) Beta blockers 
b) Antimalarials 
c) Lithium 
d) Anti convulsants 
e) NSAID’s 
f) Sudden withdrawal of systemic steroids, super potent steroids, 
coal tar, dithranol and phototherapy 
g) Others: amiodarone, clonidine, digoxin, gemfibrozil, potassium 
iodide, penicillin andterfinadine. 
 
 
9. Smoking28 
 Men who are smokers do not show an increased risk but those already 
having psoriasis will have increased expression of the disease over the 
extremities if they smoke more than 10 cigarettes per day.  
 
10. Metabolic syndrome28 
 Psoriasis being an immunologically mediated inflammatory skin 
disease, many studies substantiate the association of psoriasis with 
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comorbidities like diabetes, hypertension, lipid abnormalities, stroke and 
myocardial infarction. In a study by Anandan et al, certain parameters like 
abdominal obesity, hypertension and elevated triglycerides were found to be 
significantly associated with moderate to severe disease. 
 
 Metabolic Syndrome and psoriasis have certain immunological 
mechanisms in common. Psoriasis is associated with elevated levels of IL-6, 
plasminogen activator inhibitor type 1 and TNF-α . The elevated levels of 
these inflammatory mediators is associated with visceral adiposity. Thus the 
accumulated intra-abdominal fat starts to act as an endocrine organ secreting 
adipocytokines which affect glucose metabolism and internal biology of 
vascular endothelium and promotes inflammation. Leptin, secreted by 
adipocytes, is found to be elevated in psoriasis. It modulates the type 1 and 
2 T-helper cells by regulating cytokine expression a significant role in acute 
and chronic inflammation via regulation of cytokine expression that 
modulates the type 1 and 2 T-helper cells. Metabolic syndrome is associated 
with hyperleptinemia.  
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PATHOGENESIS34 
 Psoriasis, whether a disease of the skin or immune system, has been a 
matter of debate for several years. Cells playing a major role in pathogenesis 
are., 
 
a) Keratinocytes 
b) T cells 
c) Antigen Presenting cells 
d) Langerhans cells 
e) Natural Killer cells 
f) Macrophages 
g) Th1 cytokines 
h) Growth factors - Vascular Endothelial Growth Factor, 
Keratinocytegrowth factor. 
 
Factors playing key role in the pathogenesis are.,34 
i. T cell activation 
ii. Hyperproliferation of keratinocytes 
iii. Angiogenesis 
iv. Cytokine Mediation. 
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T cell Activation35-38 
 When an injury, either physical or chemical happens, there occurs a 
complex response involving a major interplay between cytokines and 
keratinocytes. The defective keratinocytes activates the synthesis and 
release of cytokines resulting in antigen dependent activation of T- cells. 
This leads to release of additional cytokines which will stimulate and in turn 
lead to hyperproliferation of keratinocytes35,36.  Chang et al demonstrated 
that cytokines derived from psoriatic lesions potentiate T-lymphocyte 
activation to a greater extent than those derived from normal human 
epidermal cells37. Moreover only those psoriatic keratinocytes respond well 
to T-cell supernatants than do normal keratinocytes because they contain 
specific receptors or signal transducing mechanisms38. 
 
 
HYPERPROLIFERATION OF KERATINOCYTES 39,40 
 The normal epidermal keratinocytes takes around 26 days for normal 
maturation and shedding, whereas the psoriatic epidermis takes just 4 days 
to do the same39. Growth factors derived from various cell types are 
believed to control this hyperproliferation and this forms the basis for many 
anti-psoriatic drugs of today40. 
ANGIOGENESIS41-44 
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 Keratinocytes are a richsource of  proangiogenic  cytokines like 
VEGF, IL-8  but  the exact mechanism of angiogenesis in psoriasis still 
remains elusive. The endothelial cells in a developing psoriatic plaque 
become swollen and shows  prominent Golgi apparatus andWeibel-Palade 
bodies. These cells migrate and lay down a basement membrane with 
pericytesforming structural support for an interwiningnetwork of blood 
vessels43. 
 
 This sequence of activation and swelling of endothelial cells leads to 
widened intercellular spaces and dilatation of dermal capillaries. The 
capillary  loopsin the lesional skin attain a venous morphology with bridged  
fenestrations. They also express E-selectin, making it easier for leukocyte 
migration to the skin44. 
 
 Nitric oxide is a heat labile and unstable compound is synthesized in 
endothelial cells as well as neurons by constitutive NOS synthase (cNOS), 
while inducible NO synthase (iNOS) is found in leucocytes, macrophages, 
and mesangial cells. A small amount of NO produced by cNOS in 
endothelium is responsible for the relaxation of adjacent smooth muscles 
and prevents adhesion of platelets and leucocytes to the endothelium. This is 
the anti-inflammatory effect of NO. However, when produced in large 
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amounts, Nitric oxide can destroy tissues and impair immune response. 
High levels are demonstrated in immunological disorders like systemic 
lupus erythematosus or rheumatoid arthritis. Hence, inhibition of iNOS is an 
effective modality of treatment in these conditions. The production of nitric 
oxide is approximately 10-fold higher in nonlesional skin of psoriatics and 
10-fold higher again in the plaques themselves44. 
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CYTOKINE MEDIATORS 45 
 Though a complex network of several cytokines are involved in 
mediating the pathobiology of Psoriasis, none of them seem to be causative. 
The following table illustrates the key cytokines which play a major role in 
the pathogenesis of psoriasis. 
 
CYTOKINES IN THE PATHOGENESIS OF PSORIASIS45-72 
Cytokine/Growth 
factor Role in Psoriasis 
 
TNF-α 
 
Stimulates keratinocytes to produce IL-8, ICAM-1, 
TGF-α, β-defensins, GM-CSF 
 
Enhances capacity macrophages to secrete pro-
inflammatory cytokines. 
 
Stimulates endothelial cells to produce VEGF.  
Increases keratinocyte proliferation 
 
 
 
IFN-γ 
 
Antiproliferative effect on keratinocytes  
 
Induces ICAM-1 expression on keratinocytes and  
endothelial cells 
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CYTOKINES IN THE PATHOGENESIS OF PSORIASIS45-72 
Cytokine/Growth 
factor Role in Psoriasis 
Influences trafficking of T lymphocytes into lesional 
epidermis.  
 
Stimulation of Antigen Presenting Cell activity    
Stimulates TNF-α release by phagocytes  
 
Upregulates TNF-α receptors 
 
GM-CSF 
 
Induces keratinocyte proliferation  
Activates neutrophils.  
Proliferation and migration of endothelial cells 
 
 
IL-1 
 
Induction of E-selectin and cellular adhesion 
molecules on keratinocytes 
 
Expression of KGF and GM-CSF in fibroblasts. 
Keratinocyte mitogen mediating angiogenesis 
 
 
IL-2 
 
Growth factor and chemo-attractant for T cells 
Inducer of T cell cytotoxicity. 
Stimulator of  NK cell activity.  
 
 
IL-6 
 
Enhances activation, proliferation and chemotaxis of 
T-lymphocytes in dermal infiltrate.  
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CYTOKINES IN THE PATHOGENESIS OF PSORIASIS45-72 
Cytokine/Growth 
factor Role in Psoriasis 
Induces proliferation and activation of B cells and 
macrophages.  
 
Stimulates keratinocyte proliferation. 
 
 
IL-8 
 
Migration of neutrophils and T-cells in to epidermis  
Activates and proliferates T-lymphocytes 
Stimulates angiogenesis 
 
IL-12 
 
Enhances T-cell activation and shunting into Type 1 
T cell maturation pathway 
 
 
Epidermal growth 
factor family 
 
Increases expression of TGF-α and amphiregulin. 
Increases EGF/TGF-α receptors in psoriatic 
epidermis. 
 
 
Vascular Endothelial 
Growth Factor 
 
Up-regulation in psoriasis causes erythema.  
Regulates vascular growth and remodelling 
VEGF forms a vital link between angiogenesis and 
cell-mediated inflammation. 
 
 
Fibroblast growth 
factor 
 
Mitogenic and Angiogenic properties 
Present both basally and suprabasally in psoriasis 
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CYTOKINES IN THE PATHOGENESIS OF PSORIASIS45-72 
Cytokine/Growth 
factor Role in Psoriasis 
 
Neurotrophin growth 
factor 
 
Stimulates keratinocyte and endothelial cell 
proliferation  
 
Enhances adhesion molecule expression.  
 
There is marked up-regulation of NGF receptors, 
p75 neurotrophin receptor and tyrosine kinase A , in 
the terminal cutaneous nerves of psoriatic lesions.  
 
NGF and substance P contributes to activation of T 
cells 
 
 
 
 
Endothelin-1 
 
Mitogenic to keratinocytes 
Chemo-attractant to neutrophils 
 
 
IL-23 
 
Induces Th-17 cells and activates nuclear STAT-3 
transcription.  
 
 
Th 17 
 
These cells are activated by IL-23 derived from 
antigen presenting cells(APC’s).  
 
These Th17 cells in turn produce Th17 cytokines 
namely IL-17A, IL-17F, IL-22 which bind to the 
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CYTOKINES IN THE PATHOGENESIS OF PSORIASIS45-72 
Cytokine/Growth 
factor Role in Psoriasis 
respective receptors on stromal cells to promote 
inflammation by inducing proinflammatory 
cytokines namely IL-6, IL-8, TNF-α, IL-1β). 
 
 
IL-22 
 
Acting synergistically with IL-17 it induces 
defensins, MMPs, S100A7 enhancing keratinocyte 
mobility.  
 
It increases mRNA expression of TNF-α. 
 
 
IL-17 
 
Enhances surface expression of  ICAM-1in 
fibroblast. 
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CLINICAL TYPES OF PSORIASIS73 
CLASSICAL TYPES    Psoriasis vulgaris 
       Guttate psoriasis 
       Pustular psoriasis 
       Psoriatic arthritis 
       Erythrodermic psoriasis 
 
SPECIAL TYPES    Elephantine 
Rupioid 
       Ostraceous 
 
ATYPICAL FORMS    Follicular 
       Linear 
       Lichenoid 
       Zonal 
       Verrucous 
       Seborrheic 
       Ocular 
       Mucosal 
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LOCALISED     Flexural 
       Scalp 
       Palms and Soles 
       Nail 
       Penis 
 
PALMOPLANTAR PSORIASIS74,75 
 It is one of the localized forms of  psoriasis which either can occur 
alone or along with involvement of  other areas. 
 
 The lesions in most cases are well defined plaques with less scaling 
with the surface often showing fissures. It can either be pustular or non-
pustular. 
 
The following forms of lesions can occur over palms and soles 
1. Diffuse hyperkeratotic plaques 
2. Erythematous patches and plaques with minute superficial pustules 
studded over it 
3. Discrete scaly patches and plaques 
4. Rupioid lesions over soles with characteristic limpet-like scales 
(rarely). 
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Palmoplantar psoriasis can also be classified as 
1. Pustular  - Acute pustularbacterid 
     Chronic pustularbacterid 
     Palmoplantar psoriasis with pustules 
2. Non pustular - Diffuse 
     Annular 
     Delling or crateriform 
     Marginal keratotic 
 
Noble distinguished four clinical variants of palmoplantar psoriasis: 
 
a) Typical red patches sharply demarcated and covered by adherent 
psoriatic scales. 
 
b) Diffuse mild hyperkeratosis with rhagades and scales 
 
c) Thick hyperkeratotic layer resembling hereditary type of 
palmoplantarkeratoderma 
 
d) Diffuse erythema 
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THERAPEUTIC OPTIONS FOR PALMOPLANTAR PSORIASIS 
 Various therapeutic options are available for palmoplantar psoriasis. 
These can be divided into topical, physical and systemic modalities 
 
TOPICAL76 
1. Emollients 
2. Salicylic acid 
3. Topical corticosteroids 
4. Vitamin D analogues 
5. Coal tar 
6. Dithranol 
7. Topical psoralen 
8. Topical retinoids (Tazarotene) 
9. Topical cytostatic therapy 
10. Topical tacrolimus 
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PHYSICAL77 
1. Photochemotherapy (PUVA) 
2. Narrow band UVB (311nm) 
3. Monochromatic excimer light (308nm) 
 
SYSTEMIC 78 
1. Mehotrexate 
2. Cyclosporine 
3. Acitretin 
4. Infliximab 
5. Etanercept 
 
 In our study we compare the therapeutic efficacy between one from 
each of these classes namely topical clobetasol and calcipotriol 
combination, Narrow band UVB as a physical modality and systemic 
methotrexate. 
 
TOPICAL CORTICOSTEROIDS79 
 Corticosteroids diffuse through the stratum corneum barrier and 
through cell membranes to reach the cytoplasm of keratinocytes. Diffusion 
through the stratum corneum is considered to be the rate-limiting step in 
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delivery of the drug. In the cytoplasm they bind to a specific receptor, the 
glucocorticoid receptor alpha (GRά). This binding of the receptor to its 
ligand results in activation of the receptor which dissociates from the other 
components of the tetrameric complex. 
 
 The ligand-bound receptor then enters the nuclear compartment and 
interacts with specific response elements on the genome, glucocorticoid 
response elements (GREs). This modulates transcription of numerous genes. 
In addition  the  ligand-bound receptor can inhibit, directly or indirectly, the 
activity of other transcription factors including NFκB, AP-1 and NFAT. 
These interactions lead to changes in the expression of a wide range of 
genes, resulting in diverse cellular effects which include suppression of the 
production of inflammatory cytokines, inhibition of T-cell activation, 
changes in the function of endothelial cells, granulocytes, mast cells and 
fibroblasts, and inhibition of proliferation. Part of this anti-inflammatory 
activity of corticosteroids may be explained by their ability to induce 
synthesis of  lipocortin, a family of glycoproteins which regulate the activity 
of phospholipase A2. This enzyme affects the production of arachidonic 
acid, the precursor for leukotrienes and prostaglandins.  
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 Topically applied corticosteroids are of established value in psoriasis. 
Corticosteroids have the merits of ease of application and removal, lack of 
irritancy and the absence of staining of skin or linen. Topical steroids under 
occlusion do have a definite role in managing recalcitrant psoriasis of the 
scalp, hands, feet and other areas.  
 
CLOBETASOL PROPIONATE80 
 Clobetasol propionate cream is a super potent steroid, which is one of 
the modalities of treatment of palmo plantar psoriasis. Clobetasol propionate 
gel, cream and ointment contain the active compound clobetasol propionate, 
a synthetic corticosteroid. Clobetasol, an analog of prednisolone, has a high 
degree of glucocorticoid activity and a slight mineralocorticoid activity. 
 
 Clobetasol propionate is a white to cream-colored crystalline powder 
insoluble in water. Chemically, it is 21-chloro-9-fluoro-11β 17-dihydroxy-
16β-methylpregna-1, 4-diene-3,20-dione 17-propionate, and it has the 
following structural formula:  
 
  
 Like other topical 
inflammatory, anti pruritic, and vasoconstrictive properties. Each gram of 
the 0.05% ointment contains clobetasol propionate 0.5 mg in a propylene 
glycol base, sorbitansesquioleate and white petrolatum. Its l
causes hypopigmentation, atrophy, thinning of skin, telangiectasias and 
tachyphylaxis. 
 
CALCIPOTRIOL81 
 The naturally occurring, active metabolite of vitamin D3, 1,25
dihydroxy vitamin D3 (calcitriol), and three synthetic analogues, 
calcipotriol, 1,24-dihydroxy vitamin D3 (tacalcitol) and 1,25
vitamin D3 (maxacalcitol), have proven to be effective when applied 
topically in psoriasis. 
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corticosteroids, clobetasol propionate has anti 
 
ong-term usage 
-
-dihydroxy 
  Chemically Calcipotriol is (1R,3S,5E)
[(2R,3E)-5-cyclopropyl
1H-inden-4-ylidene] ethylidene} 
 
 
 The mechanism of action of topical calcipotriol is via vitamin D
receptor-mediated effects on the proliferation and differentiation of 
epidermal keratinocytes and on the immunological features of psoriasis, 
including shifting the Th1 cytokine profile of plaques towards a Th2 
cytokine profile. 
 
 Vitamin D3 in the formof
the Vitamin D3 Receptor to regulate cell growth, differentiation and 
immune function as well as calcium and phosphorus metabolism. When the 
 
29 
 
-5-{2-[(1R,3aS,4Z,7aR)
- 5-hydroxypent-3-en-2-yl]-7a-methyl
- 4-methylidenecyclohexane
 
 1,25- dihydroxy vitamin D3 acts mainly via 
-1-
-octahydro-
-1,3-diol. 
3 
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VDR is activated by its ligand or the synthetic analogues like calcipotriol, 
the drug-receptor complex in association with retinoid X receptor- ά[ RXR- 
ά], binds to specific DNA binding sites called vitamin D3 response 
elements. Subsequently there is induction or repression of the gene that 
contains these elements.  
 
 Vitamin D3 inhibits proliferation of keratinocytes in culture and 
modulates epidermal differentiation. It promotes formation of the cornified 
envelope by increasing gene expression and protein levels of involucrin and 
transglutaminase. In addition, Vitamin D3 has a number of effects on 
inflammation. Vitamin D3 inhibits production of IL-2 and IL-6 by T cells, 
blocks transcription of IFN-γ and GM- CSF and mRNA and inhibits 
cytotoxic T- cell and natural killer cell activity.  
 
 Side effects of calcipotriol include local irritation, hypercalcaemia,  
photosensitivity and allergic contact dermatitis.  
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COMBINATION OF CALCIPOTRIOL AND CLOBETASOL 
PROPIONATE82 
 Palmoplantar psoriasis is characterized by its long term course and 
variable resistance to treatment. The three main requisites in treating such 
condition include good patient compliance, efficacious agent and low 
toxicity profile of the drug.        
 
 In a study by Katoh et al, the combination therapy with 0.0003% 
calcipotriol and 0.05% clobetasol propionate as a premixed ointment was far 
more efficacious than the monotherapy as it resulted in 50% reduction in the 
eruption score after 2 weeks, lower eruption score after 6 weeks and less 
adverse effects. 
 
PHOTOTHERAPY:84 
 The electromagnetic radiation are broadly classified into the 
following classe: 
 
1. Gamma radiation    < 100 nanometer 
2. X-ray radiation    0.01 to 10 nanometers 
3. Ultraviolet radiation A       320-400 nanometers  
4. Ultraviolet radiation B       280-320 nanometers 
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5. Ultraviolet radiation C       100-280 nanometers 
6. Visible radiation                 400-700 nanometers 
7. Infrared radiation               700 nanometers-one millimeter 
8. Terahertz radiation            one millimeter-100 microns 
9. Microwave radiation        10 millimeter-200millimeter 
10. Radio waves                     10 meters-1000 meters 
 
ULTRAVIOLET  RADIATION84 
 The wavelength of UV rays is shorter than violet end of the visible 
spectrum and longer than the X-ray. Ultraviolet light in this very shortest 
range can ionise atoms changing its physical behavior in a greater way. 
 
 At its middle range, UV rays do not ionize but break chemical bonds, 
making those molecules to be reactive unusually. For example, Sunburn, is 
found to be caused by disruptive effects of middle range UV radiation on 
skin cells, which causes skin cancer. UV rays in this range can irreparably 
damage the complex structure of DNA molecules in these cells producing 
thymine dimers making it into a very potent mutagen. 
 
 The Sun emits significant amount of UV radiation, including 
extremely short wavelength Ultraviolet light that would potentially destroy 
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most of the life on earth. Most of these Sun's most-damaging Ultraviolet 
wavelengths are absorbed by atmosphere and the ozone layer before they 
reach the earth’s surface.  
 
 The higher energy ranges of Ultraviolet light are absorbed by nitrogen 
gas and, at longer wavelengths, absorbed by simple diatomic oxygen in the 
air. Most of the Ultraviolet light in the mid-range of energy is blocked 
sufficiently by ozone layer, which absorbs wavelengths in 200–315 nm 
range, the lower part of which is too long to be absorbed by ordinary oxygen 
in air.  
 
 The  very  lowest  energy  range  of  UV  between  315 nm  and  
visible  light called  the  UV-A  neither  gets  blocked  by  the  atmosphere,  
nor  does  it  cause sunburn  and  biological  damage.  However,  it  is  not  
absolutely  harmless  and  does  produce  oxygen  radicals,  mutations  and  
eventually  skin  damage  and  cancers. 
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SKIN PHOTOTYPES85 
1. Always burns, never tans 
2. Burns always, sometimes tans 
3. Sometimes burns, always tans 
4. Never burns, always tans 
5. Moderate amount of pigmentation 
6. Deep pigmentation 
 Detailed history will determine types 1 to 4 
Types 5 and 6 can be determined by physical examination 
 
NARROWBAND UV- B IN PSORIASIS86 
 NBUVB is widely used in various dermatological conditions as a 
novel therapeutic intervention. Fisher was the first person who identified 
that narrow band ultraviolet B radiation with a wavelength of 313 (311±2) 
nanometer is efficient in clearing the lesions. Even at higher doses, no 
notable erythema is; 
 
 Jaenicke et al noted better clearance with a wavelength of 313 
nanometers87. 
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 These observations led to the invention of the artificial fluorescent 
lamps containing phosphorus (TL-01)87. 
 
 In 1988, Van Weeldenet al88 and Green et al89used the florescent 
lamps in two different studies. 
 
MECHANISM OF ACTION90,91,92: 
1. The nucleotides of DNA absorb the UVB rays which leads to 
formation of DNA photoadducts with pyrimidine dimers, thereby 
interfering with cell cycle progression and causing arrest of growth. 
2. UVB facilitates release of prostaglandins which interferes with 
expression and production of interferon and interleukins. 
3. Decreases IL-12, IL-18 IFN-γ and IL-23 expression by inducing their 
apoptosis. 
4. Depletion of T cell and NK cell activity. 
5. Suppression of Antigen presenting cell activity. 
6. Down regulation of Th 17 cells. 
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INDICATIONS93 
1. Psoriasis 
2. Atopic Dermatitis 
3. Generalised lichen planus 
4. Seborrheic dermatitis 
5. Mycosis fungoides 
6. Prurigonodularis 
7. Scleroderma 
8. Vitiligo 
9. PityriasisRosea 
10. Parapsoriasis 
11. Pruritus  
12. Pityriasisrubrapilaris 
 
CONTRAINDICATIONS93 
1. History of exposure to Aresenic 
2. History of exposure to ionizing radiation 
3. History of previous melanoma or multiple non-melanoma skin cancer. 
4. Family history of melanoma 
5. Type I skin individuals 
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Hand & Foot Phototherapy chamber  
 The chamber consists of both UVA and NBUVB lamps with a built in 
dosimetry which helped to measure the irradiation of the unit continuously.  
 
Technical data:-  
1. No. of lamps: 4 UVA & 4 NBUVB lamps  
2. Lamp wattage: 100W/6ft each  
3. Electronic timer: micro control based  
4. Reflector: aluminum (mirror type)  
5. Operating voltage: 220V to 230V, 50 Hz  
 
Patients were given protective eye glasses and genitalia were covered. 
 
PROCEDURE94: 
 Based on the Minimum Erythema Dose(MED), initial dose is 
calculated. 
 
 MED is the lowest possible dose of UVB which is able to produce a 
well defined erythema at the test site.It isusually determined 24 hours after 
exposure of UVB on back/buttocks around 1cm x 1cm. So initial dose will 
be 70% of minimal erythema dose. 
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 Minimal erythema dose for skin type 4 is 600 mJ/cm2and for skin 
type 5 is 1100mJ/cm2 as determined in a study by Pai et al. 
 
 However the latest consensus is the starting dose is determined by the 
skin type and not by minimal erythema dose 
 
 
Dose recommendations are as follows94: 
Skin type 
Initial Dose 
 (milli Joules/square 
centimeter) 
Dose 
increments(milli 
Joules/square 
centimeter) 
1 130 15 
2 220 25 
3 260 40 
4 330 45 
5 350 60 
6 400 65 
 
Erythema response is graded as95: 
a) No erythema 
b) Mild erythema –grade 1 
c) Moderate and well defined erythema – grade 2 
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d) Severe painful erythema  persisting for > 24 hours –grade 3. 
 
No erythema-Dose is increased by 20 % of last dose96 
• Grade 1 - Previous dose is maintained and subsequent dose 
   increment is reduced to 10 %. 
• Grade 2 - Postpone one treatment, repeat previous  dose at 
   next visit and reduce to 10 % increment. 
• Grade 3 - No treatment is offered until recovery and further 
   treatment is given by reducing exposure dose by 
   half and 10 % increment thereafter. 
 
 If MED is calculated, dose increment should be 10 % of initial MED 
for the initial 20 exposures and as per physicians discretion thereafter. 
 
Frequency of exposure is thrice or five times per week97. 
 If dose is missed, NBUVB can be restarted. 
• < 1 week - Maintain the last exposure dose. 
• 1-2 weeks - Restart at a dose < 25 % of the last dose. 
• 2-3weeks - Restart at 50 % depleted dose. 
• >3 weeks - Restart from the previous starting dose. 
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 In India,approach commonly practiced involves a standard starting 
dose of 280mJ/cm2 followed by stepwise increase of 20% depending on the 
patient’s erythema response97. 
 
 
SIDE EFFECTS98:  
a) Erythema 
b) Blistering 
c) Pruritis 
d) Reactivation of  herpes simplex 
e) Exposure keratitis and conjunctivitis 
f) Tanning 
 
 
ADVANTAGES OF NB-UVB OVER PUVA THERAPY98 
1. No need for intake of psoralens. Hence side effects of psoralens 
can be avoided. 
2. Useful in children under 12 years of age, where psoralen is 
contraindicated. 
3. Can be used in pregnancy and lactation, where psoralens are 
contraindicated. 
4. Can be used in elderly or those with poor hepatic or renal function. 
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5. No eye protection is necessary outside the chamber. 
6. Shorter exposure time as compared to PUVA therapy 
 
 
SYSTEMIC TREATMENT 
INDICATIONS99-103: 
1. Disabling or widespread psoriatic lesions involving more than 
20% of the body surface  area 
2. Pustular psoriasis of the Von Zumbusch type 
3. Erythrodermic psoriasis 
4. Psoriasis of palms and soles 
5. Nail psoriasis 
6. Moderate-to-severe psoriatic arthritis not controlled with NSAIDs 
7. Lack of adequate clinical response to topical agents and 
Phototherapy 
 
METHOTREXATE104-106 
 Methotrexate is an anti-folate agent and an anti-metabolite.  It was 
first synthesized in the year 1950 by Indian scientist YellapragadaSubbarao 
for targeting cancer cells. 
 
 42 
 
 
 Cell cycle specific S –phase inhibitor and thus finds its use as an anti-
cancer drug. 
 
 Although available since 1948, it was first used in the treatment of 
psoriasis from the year 1958 but was FDA approved in the year 1971 and 
was used as a DMARD from the year 1988. 
 
MECHANISM OF ACTION:106 
1. Competitively and irreversible inhibition of  
dihydrofolatereductase, preventing the conversion of dihydrofolate 
to tetrahydrofolate and thus inhibiting DNA synthesis.   
 
2. Competitive and reversible inhibition of thymidylatesynthetase and 
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) 
transformylase 
 
3. AICAR transformylase is involved in purine biosynthesis. It 
inhibits the metabolism of intracellular adenosine, which is toxic to 
T-lymphocytes and is potently anti-inflammatory.  
 
 4. It decreases the concentration of S
a pro-inflammatory mediator by blocking methionine synthet
 
5. It acts as an anti
the polymorphonuclear cells, inhibiting the C5a induced cutaneous 
inflammation, reducing the B4
of positive OK
 
6. It acts as an immunomodulating agent, breaking the production of 
IL-1 and reducing the density of Langerhans cells in the epidermis, 
and also appears to have an effect on the antigen
 
PHARMACOLOGY
CHEMICAL STRUCTURE
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-adenosylmethionine[SAM],                 
-inflammatory agent, reducing the chemotaxis of 
-induced chemotaxis and the number 
-T6 cells in the epidermis. 
-presenting cells.
107-110 
 
ase. 
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 After oral administration, it is absorbed quickly and reaches peak 
serum levels in one or two hours. After intramuscular injection, peak serum 
levels are detected within half of this time. Dairy foods and non-absorbable 
antibiotics, such as Neomycin, can reduce its bioavailability.  
 
Methotrexate diffuses and accumulates in the red globules. 50% of the 
drug binds reversibly to albumin, which means that the concomitant use of 
other medicines that also bind to proteins can increase its hematological 
toxicity. 
 
Once absorbed, the levels of Methotrexate in the plasma have a tri-
phasic reduction 
 
1. Rapid distribution phase  
2. Renal excretion phase  
3. Phase of terminal half-life 
 
 Route of elimination: 50 to 90% of methotrexate is eliminated 
through renal pathway by glomerular filtration and to a lesser extent, by 
tubular secretion. This is reduced in the presence of nonsteroidal anti-
inflammatory drugs and sulfonamides.  
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 Being a weak organic acid, it is excreted predominantly by the 
kidney, the concomitant use of other weak organic acids should be avoided 
such as salicylates and probenecidthat reduce the renal tubular transport and 
can prolong the excretion of Methotrexate.  
 
 Methotrexate has an age-dependent pharmacokinetic profile, with 
greater distribution and elimination of the drug in the young. Care must be 
exercised in older patients, due to a possible reduction in renal function. 
 
 Drugs that may increase the potential for methotrexate toxicity 
include salicylates, nonsteroidal anti-inflammatory drugs, sulfonamides, 
tetracyclines, chloramphenicol, phenytoin and phenothiazines.  
 
 If the patient has normal liver chemistry values, a normal history, and 
normal physical examination findings, and no risk factors, a liver biopsy is 
recommended after a cumulative dosage of - 1.5 gm to 2.0 gm for low risk 
patients.  
 
• 1 gm for higher risk patients. 
• Every 6 months for patients with grade IIIA liver biopsy changes  
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Classification of liver biopsy findings : 
Grade 1 : Normal : Fatty infiltration, mild; nuclear variability, mild; 
portalinflammation, mild.  
 
Grade 2 : Fatty infiltration, moderate to severe; nuclear variability, 
moderate to severe; portal tract inflammation and necrosis, moderate to 
severe.  
 
Grade 3 : A : Fibrosis, mild  
  B : Fibrosis, moderate to severe  
Grade 4 : Cirrhosis.  
  
 Two methods have been developed that might reduce the need for 
routine biopsies : 
 
a) Dynamic hepatic scintigraphy 
b) Measurement of the serum aminoterminalpropeptide of type III 
procollagen (PIIINP). 
 
Monitoring for methotrexate therapy : 
 The drug is excreted largely by the kidneys but there is 
extensiveenterohepatic cycling. The drug is 50-70% bound to plasma 
albumin. Beforetreatment, renal, hepatic and marrow function tests must be 
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normal. Urine should befree of albumin and casts. Toxic effects on the bone 
marrow include leucopenia,thrombocytopenia, folate deficient 
megaloblasticanaemia.  
 
Premethotrexate evaluation includes : 
Examination : 
1) Careful history and physical examination  
2) Identification of persons at increased risk for toxicity  
3) Recording concomitant medication that may interact with 
methotrexate.  
 
Blood : 
• Haemoglobin percentage  
• Total W.B.C. count  
• Differential count  
• Platelet count  
Liver function tests : 
• SGOT (serum glutamate oxaloacetic transaminase)  
• SGPT (serum glutamate pyruvic transaminase)  
• Serum alkaline phosphatase  
• S.bilirubin 
• S.albumin 
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Renal function tests : 
• Blood urea  
• S.creatinine 
 
Urine : 
• Sugar, albumin and cast  
• Chest radiograph  
 
During Therapy : 
1) Leucocyte count, differential count and platelet count (every week for 
4 weeks, 1 week after the last dose).  
2) Every 3-4 months, 1 week after the last dose  
• Haemoglobin estimation  
• Platelet count  
• Liver function tests  
(SGOT, SGPT, S.alkaline, phosphatase, S.albumin)  
• S.creatinine, blood urea  
• Urine analysis  
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INDICATIONS110 
FDA APPROVED 
1. Psoriasis 
2. Mycosis fungoides[cutaneous T-cell lymphoma] 
 
OFF LABEL USES 
1. Atopic dermatitis 
2. Behçet’s disease 
3. Bullous pemphigoid 
4. Cutaneous PAN 
5. Dermatitis herpetiformis 
6. Dermatomyositis 
7. IgA pemphigus 
8. Leukocytoclasticvasculitis 
9. Lupus erythematosus 
10. Lymphomatoidpapulosis 
11. Morphea 
12. Pemphigus foliaceus 
13. Pemphigus vulgaris 
14. Pityriasislichenoides et varioliformisacuta 
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15. Pityriasisrubrapilaris 
16. Pyodermagangrenosum 
17. Reiter’s disease 
18. Rheumatoid arthritis 
19. Sarcoidosis 
20. Scleroderma 
 
SIDE EFFECTS 
 
METHOTREXATE IN PSORIASIS111, 112 
 Methotrexate is an immunosuppressive agent which blocks DNA 
synthesis by inhibiting dihydrofolatereductase. It is typically given either as 
a single weekly dose of 7.5 to 25 mg per week or divided into three doses 
each week at 12-hour intervals, Weinstein & Frost, 1971.  
 
 Methotrexate is most commonly given via the oral route, however 
subcutaneous administration is also an option, Zackheim, 1992. Advantages 
of subcutaneous injections include less nausea and increased bioavailability. 
Patients may also be more familiar with self-injection because of the 
proliferation of that administration route with biologic therapy. 
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 In addition to nausea, methotrexate can cause anemia and rarely 
pancytopenia. Both of these side effects can be reduced with folic acid 
supplementation as suggested by Duhra et al and Ortiz et al. It was 
previously thought that folic acid supplementation may reduce the efficacy 
of methotrexate, but a recent review refutes by Salim et al and Strober et al 
refutes that claim. 
 
 Gilbert et al showed that patients on long-term methotrexate therapy 
also may develop cirrhosis. Risk factors for this include pre-existing liver 
disease, alcohol use, diabetes, and obesity as proposed by Langman et al. 
Though literatures in rheumatology show relatively little mention of 
screening for cirrhosis, this issue has to be viewed with so much concern 
and controversy by dermatologists.  
 
 Current American Academy of Dermatology (AAD) guidelines 
suggest a liver biopsy after each cumulative methotrexate dose of 1.5 g; 
however, studies by Aithal et al and Langman et al suggest that the first 
liver biopsy may not be necessary in patients without risk factors until 3.5 to 
4 g of methotrexate have been given. 
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 Other tests of liver function have been investigated in an attempt to 
decrease the need for liver biopsies.  Maurice et al in 2005 suggest that liver 
biopsies can be avoided if PIIINP (procollagen III) levels are consistently 
normal. Another study by Chalmers et al in 2005 showed a seven-fold 
decrease in biopsies using a PIIINP protocol compared to AAD guidelines. 
 
 Based on expert experience, the starting dose of MTX is between 5 
and 10 mg/week for the first week. Fast dose escalation is recommended in 
order to obtain a therapeutic target dose of 15–25 mg/week. The maximum 
recommended dose is 25 mg/week. A folic acid supplement is necessary. 
The initiation of treatment by oral administration is preferred. In cases 
where inadequate response is obtained or in the event of poor 
gastrointestinal tolerance, subcutaneous dosing can be proposed at the same 
dose. Published data do not confirm the incidence of hepatic fibrosis. Type 
2 diabetes and obesity appear to be significant risk factors in fibrosis. A 
combination of FibroTests and fibroscans together with measurement of the 
type III serum procollagenaminopeptide seem to be ideal method for 
monitoring liver toxicity. 
 
  
  
 
 
Aims & Objectives 
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AIM OF THE STUDY 
 
Aim of the study is to study  
 
1) To compare the therapeutic efficacy of  
A) Oral Methotrexate 
B) Hand &Foot Phototherapy using Narrowband UV-B 
C) Topical Calcitriol Plus Clobetasol Propionate Ointment  
 
2) To do Clinical evaluation using PASI scoring and assessing patient’s 
feeling of improvement using DLQI. 
 
  
  
 
 
Materials & Methods 
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MATERIALS AND METHODS 
 
 For the present study, sixty clinically diagnosed cases of palmoplantar 
psoriasis were randomly selected from the patients attending out-patient 
clinic in Department of Dermatology, Rajiv Gandhi Government General 
Hospital,Chennai from September 2013 to August 2014.  
 
 The diagnosis was based upon the clinical history and morphology of 
lesions. Doubtful cases were subjected to skin biopsy.  
 
STUDYDESIGN :  Prospective study 
 
SUBJECTSELECTION 
 
InclusionCriteria:   
 Subjects of both sexes irrespective of their age having Palmoplantar 
Psoriasis 
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ExclusionCriteria:  
1. Patients having acute uncontrolled bacterial, viral or fungal infection 
2. Patients with impaired renal function or pre-existing renal disease 
3. Patients on concomitant hepatotoxic or nephrotoxic drugs for any 
other long standing illness 
4. Pregnant or breastfeeding females 
5. Concurrent immunodeficiency state 
6. Patients having hepatitis, active or recent 
7. Patients having severe anemia, leukopenia or thrombocytopenia  
8. Photosensitive dermatoses or history of photo damage 
9. Previous or family history of malignant melanoma 
10. History of exposure to ionizing radiation 
11. Patients with hypersensitivity disorders 
12. Patients with hypercalcemia 
 
 All these patients were explained about the nature and course of the 
disease, benefits & possible side effects of treatment. Informed written 
consent were obtained from all these patients before initiation of treatment.  
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All the patients will be evaluated as follows 
 
1) History 
2) General examination 
3) Systemic examination 
4) Dermatological examination 
5) Investigations 
a) Complete hemogram 
b) Urine analysis 
c) Renal function tests 
d) Liver function tests 
e) Serum calcium, uric acid 
f) Blood VDRL 
g) Elisa for HIV 
h)  Chest X-Ray 
 
6) Skin Biopsy in doubtful cases. 
7) Opinion regarding evidence of focal sepsis from ENT & Dental 
departments 
 
  
 57 
 
 
 
TREATMENT PROTOCOL AND METHODOLOGY 
 Sixty patients with palmoplantar psoriasis were randomly allocated to 
any of the three following groups. 
 
• Group A  : Topical therapy using Calcitriol and Clobetasol 
   Ointment 
• Group B  : Physical therapy in the form of Hand and Foot  
   phototherapy usingNB-UVB 
• Group C  : Systemic therapy with oral methotrexate. 
 
GROUP A : SYSTEMIC TREATMENT USING TABLET 
METHOTREXATE 
 
20 patients were included in this group. 
 
After preliminary investigations, patients were given test dose of  
5 mg of Tablet Methotrexate, 2.5 mg to be taken 12 hours apart. 
 
After one week, blood investigations were repeated to look for 
acute myelosuppression and elevation of liver enzymes. 
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If the blood investigations were found to be normal, Patients were 
given Tablet Methotrexate 2.5 mg tablet three tablets a week with 
a total dosage of 7.5 mg per week according to Weinstein-Frost 
regimen. 
 
Patients were instructed to take the tablet after food in three 
divided doses on two consecutive days with a gap of 12 hours in 
between. 
 
Patients were followed up every 2 weeks for assessment of clinical 
response and blood investigations. Chest X-ray was repeated at the 
end of 3 months 
 
GROUP B : HAND AND FOOT PHOTOTHERAPY USING 
NARROW BAND UV-B 
• 20 patients were included in this group 
• Patients were made to sit comfortably in a chair with both the hands 
placed over the upper cubicle and the soles over the lower cubicle 
• The patients were advised to wear UV goggles 
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• Protection to the genitalia was not advised as the light rays are 
inclined at an angle away from it and protected well by clothing 
• Initial UV B dose of 0.25 J was started in all patients 
• Patients were instructed to get up from the chair once when the alarm 
starts beeping 
• If the initial dose was tolerated, 20% incremental dose was given at 
each subsequent visit depending on the patient’s erythema response. 
• Treatment was given thrice weekly on non-consecutive days. 
• Patients were monitored regularly every two weeks. 
• Patients were instructed to report immediately if any of the adverse 
effects were noted. 
 
GROUP C : TOPICAL THERAPY 
• 20 patients were included in this group 
• Patients were given free samples of an ointment containing a 
combination of  Clobetasol propionate 0.05% w/w with Calcitriol 
(Vitamin D analogue) 0.0003% w/w ointment. 
 60 
 
 
• The patients were advised to apply the ointment twice daily after 
application of emollient like liquid paraffin oil. 
• The amount of ointment to be applied was based on calculation of 
fingertip unit i.e., one fingertip unit for each hand and two 
fingertip units for each sole. 
• Patients were strictly advised not to apply the ointment over 
normal skin but only over the lesional skin 
• Patients were advised not to wash off or wipe away the ointment 
for atleast a period of 30 minutes 
• Patients were monitored regularly every two weeks for signs of 
clinical improvement 
• Patients were advised to report immediately if they observed any 
pain or burning sensation over the lesions. 
 
FOLLOW UP 
 Patients were reviewed every 4 weeks at intervals of 0,4,8,12,16 
weeks for complaints and assessing clinical improvement. These were 
compared and statistically analysed. 
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EFFICACY ASSESSMENT 
 Severity and extent of psoriasis were evaluated using “Psoriasis Area 
and Severity Index (PASI) score. 
 
 Quality of clinical improvement was assessed by Dermatology Life 
Quality index (DLQI). 
 
 Severity of Erythema (E), Desquamation (D) and Induration ( I )   
was recorded on a 5 point scale as follows.               
 
0 Nil 
1 Mild 
2 Moderate 
3 Severe 
4 Very severe 
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The  area  of  involvement  was  recorded  on  a  7  point  scale  as  follows 
0 Nil 
1 <10% 
2 10-29% 
3 30-49% 
4 50-69% 
5 70-89% 
6 90-100% 
 
 
PASI was calculated as follows 
 PASI  = Correction factor X Total score X Area of involvement 
  = 0.2 X (EU+IU+DU)X  AU+0.4 X (EL+IL+DL) X AL 
  A - Area  
  U - Upper limb 
  L - Lower limb. 
 
  
  
 
 
Observations & Results 
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OBSERVATION AND RESULTS 
 
AGE DISTRIBUTION 
         The mean age in our study group was 37.70 years in Methotrexate, 
36.85 years in NBUVB group and 35.05 years in Topical Ointmentgroup. 
The minimum age in Methotrexate, NBUVB and Topical Ointment is 22, 
20, 12 years respectively. The maximum age in Methotrexate, NBUVB and 
Topical Ointment is 56, 56, 48 years respectively. 
 
Table -1 :Showing age distribution 
Age N Mean Std. Dev Median Minimum Maximum 
MTX 20 37.70 8.82 37.00 22 56 
NBUVB 20 36.85 10.93 36.00 20 56 
TOPICAL 20 35.05 8.75 36.50 12 48 
 
  
 Figure 1 :showing mean age of patients in three groups
 
SEX DISTRIBUTION
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more in our study when compared to females.
2- showing Sex distribution 
NBUVB TOPICAL
37.7
36.85
35.05
STUDY GROUP
NBUVB TOPICAL
35
70
40
65
30
STUDY GROUP
 
 
 
 
MALE
FEMALE
  
 In Methotrexate 
NBUVB group 35 % were males, 65% were females and 
% were males, 30 % were females.
 
DURATION OF ILLNESS
 The duration of illness varied in three groups. In 
Duration of illness varied from 1 month to 30 months. In NBUVB group 
duration varied from 2 months to 30 months. In TOPICAL group duration 
of illness varied from 3 months to 26 months.
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group 60 % were males, 40% were females. In 
Topical 
 
 
Methotrexate 
 
 
duration of illness in three groups
NB UVB TOPICAL
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11.85
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STUDY GROUP
group 70 
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 The mean duration in Methotrexate group is 10.7 months, NBUVB 
group is 11.85 months, and Topical group is 11months. 
 
Table 3 :Showing duration of illness in three groups 
Duration (months) N Mean Std. Dev Median Minimum Maximum 
METHOTREXATE 20 10.7 8.16 8.5 1 30 
NB UVB 20 11.85 8.48 10.00 2 30 
TOPICAL 20 11 6.42 9.50 3 26 
 
Sites involved  
Of the cases studied the site of involvement was both palms and soles 
in 36 (60.%) cases, whereas only palms was involved in 9 (15%) cases and 
only soles involved in 15 (25%) cases. 
  
  
Table 4 : Site of involvement of Palmoplantar Psoriasis cases 
SITE OF INVOLVEMENT
Both palms and soles 
Palms 
Soles 
Total 
 
Figure 4 :Site of involvement of Palmoplantar psoriasis cases
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 NUMBER 
36 
09 
15 
60 
Palms Soles
60
15
SITE OF INVOLVEMENT
 
PERCENT 
60 
15 
25 
100 
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 In Group 1, the sites involved were both palm1s and soles in 14 
(70%) cases, only soles in 4 (20%) cases and only palms in 2 (20%) cases.  
 
 In Group 2, the sites involved were both palms and soles in 10 (50%) 
cases, only soles in 5 (25%) cases and only palms in 5 (25%) cases.  
 
 In Group 3, the sites involved were both palms and soles in 12 (60%) 
cases, only soles in 6 (30%) cases and only palms in 2 (10%) cases.  
 
Table 5 :Site of involvement in different treatment groups 
Site 
Methotrexate NBUVB Topical 
Number Percent Number Percent Number Percent 
Palms only 2 10 5 25 2 10 
Soles only 4 20 5 25 6 30 
Both palms 
and soles 14 70 10 50 12 60 
Total 20 100 20 100 20 100 
 
 Figure 5 : Site of involvement in different treatment gr
 
NAIL CHANGES 
 
 Nail changes were present in 29 of our patients, 11 in Methotrexate 
group, 7 in NB UVB group and 11 in Topical group.
 
 The commonly noted nail changes were P
Onycholysis,Subungual hyperkeratosis and R
morphological nail changes wer
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idging.  More than one 
e present in a single patient. 
 
 had pitting, threepatients had onycholysis
one patienthad ridging. 
NBUVB Topical
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In NBUVB group 
 Three patients 
patientshad subungual hyperkeratosis,
 
In Topical group 
 One patient had pitting,
subungual hyperkeratosis,
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had pitting,one patient had onycholysis,
one patienthad ridging
fourpatients had onycholysis,three patients
three patientshad ridging. 
Showing nail changes in three groups
Onycholysis Subungual 
Hyperkeratosis
Ridging
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 Eight patients had pitting, eight patients had onycholysis, eight 
patients had subungual hyperkeratosis and five patients had ridging out of 
twenty nine patients with nail involvement in all three groups of our study. 
 
Table 6 :Showing nail involvement in three groups 
Group 
Nail Involvement 
Total 
Pitting Onycholysis Subungual Hyperkeratosis Ridging 
Methotrexate 4 3 3 1 11 
NB-UVB 3 1 2 1 7 
Topical 1 4 3 3 11 
Total 8 8 8 5 29 
 
  
 Table 7 :Showing 
 
Nail finding
Pitting 
Onycholysis
Subungual hyperkeratosis
Ridging 
 
 
 
Figure 7 : Showing percentage of nail involvement in three groups
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percentage of nail involvement in three groups
 Percentage 
27.58% 
 27.58% 
 27.58% 
17.24% 
 
 
 
27.58%
27.58%
27.58%
17.24%
Onycholysis Subungual hyperkeratosis Ridging
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OTHER SITES 
No patients had mucous membrane, scalp, joint involvement. 
 
PASI REDUCTION 
 The following tables shows the mean PASI score  at baseline and 
reduction of mean PASI score at 4 weeks, 8 weeks, 12 weeks, 16 weeks in 
PUVA, NBUVB, PUVASOL groups. 
 
 The mean PASI score at baseline (Table 8) was 30.98 in Methotrexate 
group, 28.19 in NBUVB group, and 26.66 in TOPICAL group. The 
minimum mean PASI score at baseline in Methotrexate, NBUVB and 
Topical group is 20.0, 22.4 and 19.2 respectively. The maximum mean 
PASI score at baseline in PUVA, NBUVB and PUVASOL group is 39.4, 
36.8 and 32.8 respectively. 
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Table 8:Showing mean PASI score at baseline in three groups 
PASI 0 N Mean Std. Dev Median Minimum Maximum 
MTX 20 30.98 5.32 31.29 20.0 39.4 
NBUVB 20 28.19 4.21 28.10 22.4 36.8 
TOPICAL 20 26.66 3.99 26.90 19.2 32.8 
 
 The mean PASI score at 4 weeks (Table 9) was 16.34 in Methotrexate 
group, 17.19 in NBUVB group, and 14.91 in TOPICAL group.  
 
 The minimum mean PASI score at 4 weeks in PUVA, NBUVB and 
PUVASOL group is 10.2, 12.0, and 10.0 respectively. The maximum mean 
PASI score at 4 weeks in PUVA, NBUVB and PUVASOL group is 22.2, 
22.8 and 20.2 respectively. 
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Table 9 :Showing mean PASI score at 4 weeks in three groups 
PASI 4 N Mean Std. Dev Median Minimum Maximum 
MTX 20 16.34 2.85 16.10 10.2 22.2 
NBUVB 20 17.19 3.23 17.80 12.0 22.8 
TOPICAL 20 14.91 2.17 15.0 10.0 20.2 
 
 The mean PASI score at 8 weeks (Table 10) was 10.12 in 
Methotrexate group, 11.42 in NBUVB group, and 12.04 in Topical group. 
 
 The minimum mean PASI score at 8 weeks in Methotrexate, NBUVB 
and Topical group is 4.4, 6.4, and 5.6 respectively. The maximum mean 
PASI score at 8 weeks in Methotrexate, NBUVB and Topical group is 13.4, 
18.4 and 13.4 respectively. 
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Table 10 :Showing mean PASI score at 8 weeks in three groups 
PASI 8 N Mean Std. Dev Median Minimum Maximum 
MTX 18 10.12 3.95 10.40 4.4 13.4 
NBUVB 19 11.42 3.49 11.10 6.4 18.4 
TOPICAL 18 12.04 2.13 12.25 5.6 13.4 
  
The mean PASI score at 12 weeks (Table 10) was 3.40 in 
Methotrexate group, 5.20 in NBUVB group, and 5.60 in Topical group. 
 
The minimum mean PASI score at 12 weeks in Methotrexate, 
NBUVB and Topical group is 0.0, 0.0 and 2.2 respectively. The maximum 
mean PASI score at 12 weeks in Methotrexate, NBUVB and Topical group 
is 7.6, 7.2 and 7.8 respectively. 
 
  
 77 
 
 
 
 
Table 11 :Showing mean PASI score at 12 weeks in three groups 
PASI 12 N Mean Std. Dev Median Minimum Maximum 
MTX 20 3.40 2.23 3.15 0.0 7.60 
NBUVB 13 5.40 3.61 5.60 0.0 7.20 
TOPICAL 20 5.60 2.81 5.80 2.2 7.80 
 
 The mean PASI score at 16 weeks (Table 11) was 0.49 in 
Methotrexate group, 1.76 in NBUVB group, and 1.45 in TOPICAL group. 
The minimum mean PASI score at 16 weeks is 0.0 in all three groups. The 
maximum mean PASI score at 16 weeks in Methotrexate, NBUVB and 
Topical group is 3.2, 3.4 and 4.2 respectively. 
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Table 12 :Showing mean PASI score at 16 weeks in three groups 
PASI 16 N Mean Std. Dev Median Minimum Maximum 
MTX 19 0.49 0.81 0.00 0.0 3.2 
NBUVB 13 1.76 1.51 0.00 0.0 3.4 
TOPICAL 20 1.45 2.20 3.60 0.0 4.2 
 
 From tables 8-12 we inferred that there was gradual reduction in 
PASI score in all three groups. 
 
Table 13 :Shows mean reduction in PASI score among three groups 
Duration 
Mean PASI score 
MTX NBUVB TOPICAL 
Baseline 30.98 28.19 28.66 
4 weeks 16.34 17.19 14.91 
8weeks 10.12 11.42 12.04 
12 weeks 3.40 5.40 5.60 
16 weeks 0.49 1.76 1.45 
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 In Methotrexate group the mean PASI score at baseline is 30.98 and it 
was reduced to 0.49 at 16 weeks.  
 
 In NBUVB group the mean PASI score while enrolling in study was 
28.19 where as it was reduced to 1.76 at 16 weeks.    
 
 In Topical group the mean PASI score was 28.66 at baseline and it 
was reduced to 1.45 at 16 weeks of Topical therapy. 
 
Therefore the mean reduction of PASI score at 16 weeks is more in 
Methotrexate group, followed by Topical group. NBUVB has lesser 
reduction in mean PASI score among three groups. 
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Figure 8: Showing mean reduction in PASI scores 
 
 
 
 Table 14 shows P values by comparing three groups with one another. 
There was no statistically significant reduction in PASI score at 0, 4, 8, 12 
and 16 weeks when MTX and NBUVB are compared. 
 
          When MTX and TOPICAL groups are compared there is no 
statistically difference in reduction in PASI score at 0, 4, 8 weeks. But at 12 
and 16 weeks there is statistically significant (P<0.001) reduction in PASI 
score. 
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Table 14 :Shows P values of PASI Score reduction  
when twogroups are compared 
 
Variables 
P-Values 
MTXvs 
NBUVB NBUVBvsTOPICAL MTXvsTOPICAL 
PASI 0 0.579 0.903 0.695 
PASI 4 0.933 0.255 0.184 
PASI 8 0.627 0.024 0.101 
PASI 12 0.150 0.001 0.035 
PASI 16 0.694 0.001 0.001 
 
          When NBUVB and TOPICAL groups were compared there was no 
statistically significant difference in PASI score at 0, 4, 8, 12 weeks. 
However at 16 weeks there is statistically significant PASI reduction 
(P<0.001). 
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PERCENTAGE REDUCTION OF PASI SCORE 
Table 15 :Showing percentage mean reduction in  
PASI score in three groups 
Duration MTX NBUVB TOPICAL 
Baseline 0 0 0 
4 weeks 36.2 30.99 31.89 
8 weeks 67.5 59.2 64.94 
12 weeks 91.0 72.0 80.53 
16 Weeks 98.9 82.9 86.44 
 
 
 The above table shows that there is gradual increase in percentage 
mean reduction of PASI score over weeks. When compared to baseline 
mean PASI score there was 98.9 % reduction in mean PASI score at 16 
weeks in MTX group and 82.9% reduction in mean PASI score at 16 weeks 
in NBUVB group. In TOPICAL group there is 86.44% reduction in mean 
PASI score at 16 weeks. 
 
 MTX group has the maximum percentage reduction in mean PASI 
score at 16 weeks, followed by TOPICAL group. NBUVB shows least 
reduction when all three groups are compared. 
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RESPONSE TO THERAPY 
 Based on percentage reduction in PASI score the results were graded 
as excellent (100%), good (75-100%), moderate (50- 75%) and poor (< 
50%). 
 
RESPONSE TO THERAPY IN METHOTREXATE GROUP 
In Methotrexate group out of 20 patients 15 patients had complete 
clearance at 16 weeks and 4 had good response. 1 patient discontinued 
treatment at 16 weeks of therapy due to intolerance to drug. 
 
Table 16:Response to treatment in Methotrexate group 
Results No. of patients Percentage 
% reduction 
in PASI score 
at 16 weeks 
Excellent 15 75.00 100 
Good 4 20.00 75-100 
Moderate - - 50-75 
Poor response - - <50 
Discontinued 1 5.00 - 
 
 
 Therefore in Methotrexate group 75.00% of patients had excellent 
response and 20.00 % of patients had good response at 16 weeks. 
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RESPONSE TO THERAPY IN NBUVB GROUP 
 In NBUVB group out of 20 patients 9 patients had complete clearance 
at 16 weeks and 3 had good response 1 patients had poor response.  
7 patients discontinued treatment at 12 weeks of therapy due to unknown 
reasons 
 
Table 17 :Response to treatment in NBUVB group 
Results No. of patients Percentage 
% reduction 
in PASI score 
at 16 weeks 
Excellent 9 45.00 100 
Good 3 15.00 75-100 
Moderate - - 50-75 
Poor response 1 5.00 <50 
Discontinued 7 35.00 - 
 
 
 Therefore in NBUVB group 45.00% of patients had excellent 
response and 15.0 % of patients had good response at 16 weeks. 5.0% had 
poor response. 
  
 85 
 
 
 
RESPONSE TO THERAPY IN TOPICAL GROUP 
 7 patients had complete clearance at 16 weeks and 13 had good 
response. None of the patients discontinued therapy. 
 
 Therefore in Topical group 15 % of patients had excellent response 
and 60 % of patients had good response at 16 weeks. 15% had poor 
response 
 
Table 18: Response to treatment in TOPICAL group 
Results No. of patients Percentage 
% reduction 
in PASI score 
at 16 weeks 
Excellent 7 35.00 100 
Good 13 65.00 75-100 
Moderate - - 50-75 
Poor response - - <50 
Discontinued - - - 
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SIDE EFFECTS 
 
 In Methotrexate group  
• 3 patients developed nausea 
• 1 patient had gastritis  
 
             In NBUVB group  
• 1 patient developed erythema 
• 1 patient had initial exacerbation 
• 3 patients had recurrence 
 
In Topical group 
• 7 patients had recurrence 
• 3 patients developed irritation 
  
 Figure 9 :
Dermatology Life Quality Index evaluation in three different groups 
 A questionnaire assessing the extent to which patients suffer in 
carrying out day to day activities was used to assess the Dermatology Life 
Quality Index and the results are tabulated as follows
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Showing adverse effects in three groups
 
 
 
Gastritis Irritation Erythema Initial 
exacerbation
1 1 1
3
ADVERSE EFFECTS
MTX NBUVB TOPICAL
 
 
 
Recurrence
3
7
 Table 21 showing Dermatolog
Weeks 
Baseline 
4 weeks 
8 weeks 
12 weeks 
16 weeks 
 
Figure 10: Showing improvement in Dermatology Life Quality Index
 
 
 
 
88 
 
y Life Quality index evaluation
Dermatology Life Quality Index points
MTX group NB-UVB group 
35 34 
23 27 
17 20 
11 14 
4 10 
 
 
 
Topical group 
32 
28 
21 
15 
9 
 
 
 Figure 11: Showing quality of improvement in MTX group
Figure 12: Showing quality of improvement in NBUVB group
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 Figure 13: Showing quality of improvement in
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 Topical
 
 group 
 
MTX - BASELINE
MTX - 4 WEEKS
MTX - 8 WEEKS
MTX - 16 WEEKS
NBUVB - BASELINE
NBUVB - 4 WEEKS
NBUVB  - 8 WEEKS
NBUVB  - 16 WEEKS
TOPICAL - BASELINE
TOPICAL - 4 WEEKS
TOPICAL - 8 WEEKS
TOPICAL - 16 WEEKS
  
 
 
Discussion 
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DISCUSSION 
 
 Palmoplantar psoriasis is a localized form of psoriasis characterized 
by erythema, hyperkeratosis with surrounding lichenification and coarse 
scale, resulting in peeling, blistering, crusting, fissuring and bleeding. These 
symptoms may significantly interfere with activities, inhibiting patients 
from working with their hands or walking on their feet comfortably leading 
to major disability and reduction in quality of life. Once established, it 
might last for decades and can cause impaired dexterity or mobility, as well 
as discomforting pruritus and pain. This type of psoriasis is also chronic 
with frequent exacerbation, difficulty in management and resistant to 
therapy74,75.  
 
 The treatment modalities for psoriasis can be divided into topical, 
physical and systemic agents. Here in this study we compared the 
therapeutic response to drugs, one from each of these modalities namely 
methotrexate, a systemic treatment modality, NB-UVB, a physical treatment 
modality and a combination of clobetasol propionate with calcitriol 
ointment as a topical treatment modality. There are very few studies 
comparing the therapeutic efficacy between these agents and there is no 
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single study comparing the efficacy of Methotrexate, NB-UVB and Topical 
Calcitriol 0.0003% with Clobetasol Propionate 0.05% ointment. 
 
          We enrolled 60 patients with palmoplantar psoriasis not involving 
other body areas. They were randomly divided into three groups.  
 
           All three groups were well matched in terms of age, duration of 
lesions and baseline PASI score. They were followed up weekly after 
initiating treatment. PASI score were calculated at 0, 4, 8, 12 and 16 weeks. 
 
AGE DISTRIBUTION: 
Palmoplantar Psoriasis may affect people of all ages.  In this study 
age group ranged from 12 years to 56 years with mean age of 30 years. This 
was in concurrence with the with the age incidence of earlier studies of 
Spuls et al115 which showed mean age of onset 28 years. Similarly, Sharma 
et al113 and Lal et al114 showed highest incidence to be in the second decade. 
 
SEX DISTRIBUTION :  
In the current study, male patients constituted the majority. This 
concurred with most of the Indian studies.113-115 
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          The higher incidence in males could be explained by the fact that 
though there is no strict variation in the occurrence of the disease in both 
sexes, the male patients come forward for examination and treatment where 
as, there is a hesitancy on the part of females to come forward for treatment, 
for fear of social stigma and rejection.115 
 
DURATION OF ILLNESS 
 The duration of illness varied in three groups. In Methotrexate group  
duration of illness varied from 1 month to 30 months. Similar study by 
Mehta et al 116 showed where duration of illness between 13-48 months. 
 
In NBUVB group duration of illness varied from 2 months to 30 
months. Lal et al114 showed duration of illness between 18 months to 3 
years.  
 
In topical group duration of illness varied from 3 months to 26 
months. This correlates with the study by Lafah et al114 
 
OCCUPATIONAL STATUS 
 In this study, the majority of patients were manual labourers. The next 
majority of patients were housewives, drivers, mechanics and students. 
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Majority of the patients were manual labourers and housewives which could 
be attributed to occupational trauma. This is similar to study by Stewart et al 
117and Paul et al 118 
 
COMPARISON OF METHOTREXATE, NBUVB & TOPICAL 
CALCITRIOL WITH CLOBETASOL PROPIONATE BASED ON 
PASI SCORING 
 
 In methotrexate group the mean baseline PASI score is 30.98 and 
mean PASI score at 16 weeks is 0.49. Therefore there is 98.4% reduction in 
PASI score at end of 16 weeks. Dhir et al112 showed PASI reduction of 93% 
in 12 weeks.  
 
In NBUVB group the mean baseline PASI score is 28.19 and at mean 
PASI score at 16 weeks is 1.76. PASI reduction was 93.75% at the end of 
16 weeks. Dayal et al 120 showed 84% PASI reduction in a 12 week study.  
 
In Topical group the mean baseline PASI score is 28.66 and mean 
PASI score at 16 weeks is 1.45. Therefore there is 94.94% reduction in 
PASI score at end of 16 weeks. Lafah et al123 showed PASI reduction of 
86% in 16 weeks.  
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PASI 75 was attained at 8-12 weeks in Methotrexate group and PASI 
75 was attained at 12-16 weeks in NBUVB group. This is in concurrence 
with Dhir et al112. PASI 75 was attained in 10-12 weeks in Topical group in 
close concordance with the study by Lafah et al123.  
 
All three groups showed appreciable clearance in lesions at the end of 
16 weeks but it took a longer time to achieve PASI 75 in NBUVB group and 
topical group than in Methotrexate group in concurrence with Paul et al120 
and Lafah et al123.   
 
SIDE EFFECTS 
Nausea and gastritis were observed as side effects in Methotrexate 
group as in Dhir et al112. Other side effects which were reported in that study 
were not present here. 
 
In NBUVB group, the side effects noted were erythema followed by 
pruritus. This was seen to be similar to studies by Paul et al119 and 
Asawanonda et al122. Initial exacerbation was noted in 1 of our patients in 
NBUVB group, but newer lesions ceased to appear with continuation of 
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therapy. This correlated with Piskin et al, Woo WK et al and Collins et 
al(125-127). 
 
In Topical group, irritation was noted as a side effect. This was in 
concordance with Gallini et al 124 
 
RELAPSE OF DISEASE 
No relapse cases were reported in methotrexate group in the follow-
up period of 8 weeks. Dhir et al112 reported 2 relapse cases in a follow-up 
period of 1 year. 
 
NBUVB group had 3 relapse cases. Dayal et al120 reported 2 relapse 
cases among 46 patients treated with NB-UVB and followed up for 1 year. 
 
Topical group had 7 relapse cases. Lafah et al123 reported 3 relapse 
cases among 60 patients. 
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COMPLIANCE 
Compliance and adherence to treatment regime was better in 
methotrexate group as no drop-outs were reported. This was concurrent with 
studies by Dhir et al112 and Lafah et al123. In NB-UVB group follow-up was 
lost with seven patients. This correlated with the study by Dayal et al120 
  
  
 
 
Conclusion 
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CONCLUSION 
• Methotrexate therapy is the most effective modality of treatment in 
palmoplantar psoriasis. 
• NBUVB therapy has equal efficacy to topical clobetasol with 
calcitriol therapy in our study. 
• The mean PASI reduction is almost equal for both NBUVB therapy 
and topical clobetasol with calcitriol therapy. 
• DLQI questionnaire proved to be a useful tool in assessing patient’s 
subjective improvement after initiation of treatment 
• There were no dropouts in methotrexate and topical therapy group 
compared to NB-UVB group. 
• When NBUVB and Topical Clobetasol and Calcitriol are compared 
there is no statistically significant difference in mean PASI score 
reduction at 16 weeks.  
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• Based on compliance and adherence to treatment, topical clobetasol 
with calcitriol therapy scores over the NBUVB therapy. 
• When methotrexate therapy is compared with NB-UVB and topical 
clobetasol with calcitriol ointment therapy, the rate of clearance of 
lesions in latter groups were poor. 
• All the side effects noted in this study were minor and they were 
treated conservatively. 
• This shows that all three treatment groups namely systemic 
methotrexate, NB-UVB phototherapy and topical clobetasol with 
calcitriol ointment achieved >75% or complete clearance at end of 16 
weeks. In methotrexate group clearance of lesions was faster with less 
side effects.  
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• In NBUVB and topical clobetasol with calcitriol treatment groups 
lesions took longer time to resolve and also recurrence of lesions were 
reported.  
• Compliance was less with NB-UVB group among the three groups.  
• Post treatment follow-up visits were better among the methotrexate 
group and topical clobetasol with calcitriol ointment group. 
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PROFORMA 
 
Name:       Date: 
Age:        OP No: 
Sex:        Case No: 
Occupation: 
Address: 
 
HISTORY: 
Complaints:                                               
Duration: 
Itching:   Yes/No 
H/o Previous treatment:     Topical/Systemic 
 
PAST HISTORY: 
Diabetes Mellitus  Hypertension   Tuberculosis 
Photosensitivity  Cutaneous Malignancy  Radiotherapy 
 
DRUG TAKEN FOR ANY OTHER CONDITION: 
If yes    Name of the drug  Duration of treatment 
 
FAMILY HISTORY: 
PERSONAL HISTORY: 
Smoking: 
Alcohol: 
MENSTRUAL HISTORY: 
PREGNANCY: 
LACTATION: 
GENERAL EXAMINATION: 
Pallor 
Icterus 
Edema 
Pulse 
Blood Pressure 
Weight 
 
SYSTEMIC EXAMINATION: 
CVS 
RS 
P/A 
CNS 
ENT 
DENTAL 
DERMATOLOGICAL EXAMINATION: 
Skin lesions  Site 
   Morphology 
   Other sites 
Mucous membranes 
Scalp 
Hair 
Nails 
 
  
AREA & SEVERITY ASSESSMENT BY PASI SCORING: 
Erythema/ Infiltration/ Desquamation  Area scoring 
Scoring 
0- Nil       0- Nil 
1- Mild       1- 0-9% 
2- Moderate      2- 10-29% 
3- Severe      3- 30-49% 
4- Very severe      4- 50-69%   
       5- 70-89%   
       6- 90-100% 
PASI will be calculated as follows 
PASI = 0.2(EU+IU+DU)AU + 0.4(EL+IL+DL)AL 
A – Area U- Upper limb       L- Lower limb 
 
INVESTIGATIONS: 
Total count: 
Differential count: 
ESR: 
Hb: 
Blood sugar 
Urea 
Creatinine: 
Serum calcium: 
VDRL: 
VCTC: 
LFT: 
 
  
PASI SCORING 
Week PASI score % Improvement 
0 
 
4 
 
8 
 
12 
 
16 
  
 
 
 
MASTER CHART – METHOTREXATE 
 
S. 
NO 
AGE SEX DURATION OCCUPATION SITE NAIL JOINT BODY SCALP PASI 0 PASI 4 PASI 8 PASI 12 PASI 16 
SIDE 
EFFECTS 
RECURRENCE 
1 33 F 2Y HOUSEWIFE 
PALMS 
& SOLES 
P N N N 34 22.2 10.8 4.6 0 N N 
2 36 F 8M HOUSEWIFE SOLES P N N N 20.2 12 5.4 1.2 0 N N 
3 43 M 7M LABOURER SOLES N N N N 20 10.2 4.4 0 0 N N 
4 56 M 2Y 6M FARMER 
PALMS 
& SOLES 
O, SUH N N N 32.4 17.6 8.8 7.6 DISC0NTINUED GASTRITIS N 
5 31 M 1Y LABOURER 
PALMS 
& SOLES 
N N N N 33.6 18.8 9.8 3.6 0 N N 
6 38 M 1Y 3M MECHANIC SOLES O,R N N N 29.4 15.4 7.8 2.2 0 N N 
7 50 M 8M HOUSEWIFE 
PALMS 
& SOLES 
SUH N N N 31.4 16.2 8.6 5.4 0 NAUSEA N 
8 48 F 1Y 7M MECHANIC 
PALMS 
& SOLES 
N N N N 37.4 19.2 10.2 3.8 0 N N 
9 37 M 1Y 1M LABOURER 
PALMS 
& SOLES 
N N N N 30.2 15 7.2 5.2 2.6 N N 
10 25 M 3M PROFESSIONAL 
PALMS 
& SOLES 
N N N N 31.2 16 9.2 4.4 0 N N 
11 48 M 9M DAILY WAGER SOLES N N N N 29.6 14.8 7.2 3.6 0 N N 
12 37 F 6M TEACHER 
PALMS 
& SOLES 
N N N N 33.8 17 8.8 6.2 3.2 NAUSEA N 
13 28 M 2M HOUSEWIFE 
PALMS 
& SOLES 
O,SUH N N N 34.6 17.2 8.8 5.4 1.4 N N 
14 40 F 3M MECHANIC 
PALMS 
& SOLES 
N N N N 37.8 19 10.2 5.4 0 N N 
15 33 M 4M LABOURER PALMS N N N N 27 14 6.8 0 0 N N 
16 46 M 1Y, 2M HOUSEWIFE PALMS P N Y N 29 14 6.2 0 0 N N 
17 35 F 10M HOUSEWIFE 
PALMS 
& SOLES 
N N N N 29.8 15.2 7.8 2.4 0 N N 
18 29 F 1Y 9 M PROFESSIONAL 
PALMS 
& SOLES 
N N N N 36.2 18.6 10.2 3.4 0 N N 
19 22 M 1Y 4M STUDENT 
PALMS 
& SOLES 
N N N N 39.4 20 13.4 6.8 2.2 NAUSEA N 
20 39 F 1M HOUSEWIFE 
PALMS 
& SOLES 
P N N N 27.6 14.4 7.6 3 0 N N 
 
MASTER CHART – NBUVB 
S.NO AGE SEX DURATION OCCUPATION SITE NAIL JOINT BODY SCALP 
PASI 
0 
PASI 
4 
PASI 
8 
PASI 
12 
PASI 
16 
SIDE EFFECTS RECURRENCE 
1 39 F 1Y, 2M HOUSEWIFE PALMS & SOLES N N N N 29.4 19.6 12.4 5.6 2.6 
INITIAL  
EXACERBATION 
Y 
2 36 M 6M MECHANIC SOLES N N N N 27.6 18.4 12.6 DISCONTINUED N 
LOST  
FOLLOWUP 
3 22 M 3M STUDENT PALMS N N N N 22.4 12.4 6.4 0 0 N N 
4 50 F 1Y, 6M HOUSEWIFE PALMS & SOLES N N N N 33.8 22.4 18.4 DISCONTINUED 
 
LOST  
FOLLOWUP 
5 36 F 1Y HOUSEWIFE PALMS & SOLES N N N N 31.2 18.8 9.4 4.6 0 N N 
6 32 F 8M TYPIST PALMS N N N N 25.6 15.4 7.8 3.6 0 N N 
7 47 F 1Y, 5M HOUSEWIFE SOLES N N N N 30.4 22.8 17.2 DISCONTINUED N 
LOST  
FOLLOWUP 
8 30 F 1Y, 8M CLERICAL PALMS & SOLES N N N N 36 19.6 9.8 4.6 0 N N 
9 49 M 1Y 
DAILY  
WAGER 
SOLES N N N N 29.2 17.6 12.8 DISCONTINUED N 
LOST  
FOLLOWUP 
10 53 M 2Y, 4M 
DAILY  
WAGER 
PALMS & SOLES SUH N N N 30.4 20.8 14.4 DISCONTINUED ERYTHEMA 
LOST  
FOLLOWUP 
11 56 M 2Y,6M WATCHMAN PALMS N N N N 22.8 16.8 9.8 DISCONTINUED N 
LOST  
FOLLOWUP 
12 33 F 1Y HOUSEWIFE PALMS N N N N 23.8 12 6.4 2.8 0 N N 
13 29 F 1Y, 8M TYPIST SOLES P N N N 24.8 15.4 8.8 4 0 N N 
14 39 F 7M HOUSEWIFE PALMS & SOLES O N N N 36.8 19 10.4 7.2 3.4 N Y 
15 22 F 2M STUDENT SOLES N N N N 29.4 15 8.8 5.4 2.2 N N 
16 20 F 2M STUDENT PALMS & SOLES P N Y N 23.8 13 6.8 2.4 0 N N 
17 50 M 8M BUSINESS PALMS SUH, P N N N 26.8 18.4 13.6 DISCONTINUED N 
LOST  
FOLLOWUP 
18 38 M 1Y, 5M MECHANIC PALMS & SOLES R N N N 26.4 16.4 11.6 6.4 3 N Y 
19 30 F 7M HOUSEWIFE PALMS & SOLES N N N N 27.4 18 11.2 7 2.8 N N 
20 26 F 5M IT PALMS & SOLES N N N N 22.8 12 7.6 2.8 0 N N 
 
MASTER CHART – TOPICAL CLOBETASOL + CALCITRIOL  
 
S.NO AGE SEX DURATION OCCUPATION SITE NAIL JOINT BODY SCALP PASI 0 PASI 4 PASI 8 PASI 12 PASI 16 
SIDE 
EFFECTS 
RECURRENCE 
1 38 F 2Y HOUSEWIFE 
PALMS & 
SOLES 
P N N N 32 20.2 10.8 5.6 2.4 N Y 
2 43 M 5M LABOURER SOLES O N N N 26.4 13 6.8 2.2 0 N N 
3 41 M 9M LABOURER 
PALMS & 
SOLES 
N N N N 31.2 16.2 9.8 4.4 2.2 N N 
4 48 M 1Y 6M FARMER 
PALMS & 
SOLES 
O,SUH N N N 30.4 14.8 9 5.2 3 N N 
5 37 F 8M HOUSEMAID SOLES N N N N 24.8 11.6 7.8 3.6 0 IRRITATION N 
6 35 M 1Y, 7M MECHANIC SOLES O,R N N N 22.8 14.4 7.8 5.4 2.6 N Y 
7 29 M 3M HOUSEWIFE PALMS SUH N N N 21.4 10.4 5.6 2.8 0 N N 
8 44 F 9M MECHANIC SOLES N N N N 22.8 16.4 11.2 6.4 3.2 N Y 
9 46 M 2Y, 2M LABOURER 
PALMS & 
SOLES 
N N N N 28.4 16.4 10 6.4 3 N Y 
10 25 F 4M TEACHER 
PALMS & 
SOLES 
N N N N 19.2 12 6 2.8 0 N N 
11 39 M 9M DAILYWAGER 
PALMS & 
SOLES 
O N N N 26.8 14.8 8 4.4 1.2 IRRITATION N 
12 37 M 1Y, 2M LABOURER 
PALMS & 
SOLES 
N N N N 32.8 16.4 9.2 6 3 N Y 
13 30 M 5M MECHANIC 
PALMS & 
SOLES 
N N N N 27.2 15.6 8.8 5 1.8 N Y 
14 23 M 3M STUDENT 
PALMS & 
SOLES 
N N N N 30.4 16.8 10.2 5.4 0 N N 
15 35 M 10M LABOURER 
PALMS & 
SOLES 
N N N N 27 13 6.8 3.4 0.8 N N 
16 43 F 1Y, 7M HOUSEWIFE 
PALMS & 
SOLES 
R N Y N 29.4 15 7.8 5 1.4 IRRITATION N 
17 29 F 11M HOUSEWIFE 
PALMS & 
SOLES 
R N N N 30.6 15.2 7.8 2.4 0 N N 
18 36 M 1Y, 9M MECHANIC 
PALMS & 
SOLES 
N N N N 25.6 16.2 10.2 7.8 4.2 N N 
19 12 M 4M STUDENT SOLES N N N N 22.4 15 13.4 6.8 2.2 N N 
20 31 M 11M LABOURER SOLES SUH N N N 21.6 14.8 8.8 5.2 0 N Y 
 
ABBREVIATIONS 
 
 
PPP    – Palmoplantar Psoriasis 
Mtx   – Methotrexate 
NBUVB   – Narrow band ultraviolet B 
UV-A   – Ultraviolet A 
UV-B   – Ultraviolet B 
HLA    – Human Leucocyte Antigen 
NSAID’s   – Non Steroidal Anti-inflammatory Drugs 
IL    – Interleukin 
TNF   – Tumor Necrosis Factor 
NOS    – Nitric Oxide Synthase 
PUVA   – Psoralen Ultraviolet A 
GRα    – Glucocorticoid Receptor α 
GRE    – Glucocorticoid Response Elements 
RXR    – Retinoid X Receptor 
MED    – Minimum Erythema Dose 
PAN    – PolyarteritisNodosa 
PIIINP   – Procollagen III aminopeptide 
DLQI   – Dermatology Life Quality Index 
 
